Schechter Investment Advisors LLC Has $1.02 Million Stock Position in Grifols, S.A. (NASDAQ:GRFS)

Schechter Investment Advisors LLC cut its holdings in Grifols, S.A. (NASDAQ:GRFS) by 9.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 88,245 shares of the biotechnology company’s stock after selling 9,154 shares during the period. Schechter Investment Advisors LLC’s holdings in Grifols were worth $1,020,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital World Investors increased its holdings in Grifols by 15.2% during the first quarter. Capital World Investors now owns 17,172,143 shares of the biotechnology company’s stock worth $200,571,000 after buying an additional 2,265,005 shares during the last quarter. Norges Bank bought a new stake in Grifols during the fourth quarter worth $19,218,000. Point72 Asset Management L.P. bought a new stake in Grifols during the second quarter worth $17,484,000. Bank of America Corp DE raised its position in Grifols by 69.9% during the first quarter. Bank of America Corp DE now owns 4,274,707 shares of the biotechnology company’s stock worth $31,505,000 after acquiring an additional 1,759,321 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Grifols by 122.0% during the second quarter. Goldman Sachs Group Inc. now owns 3,048,969 shares of the biotechnology company’s stock worth $36,222,000 after acquiring an additional 1,675,639 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GRFS shares. Deutsche Bank Aktiengesellschaft downgraded shares of Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th. JPMorgan Chase & Co. upped their price objective on shares of Grifols from $10.00 to $10.50 and gave the company a “neutral” rating in a report on Tuesday, December 5th.

Grifols Price Performance

GRFS stock opened at $6.65 on Thursday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.32 and a current ratio of 2.83. The company’s 50-day simple moving average is $7.50 and its 200 day simple moving average is $8.71. Grifols, S.A. has a 52 week low of $5.30 and a 52 week high of $12.15.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product.